Trial · NCT07428369
Registered outcomes74
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 40 of 74
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Duration of ≥CR per IMWG criteria | Up to 5 years | |
| Secondary | PFS per IMWG criteria | Up to 5 years | |
| Secondary | Second PFS (PFS2) per IMWG criteria | Up to 5 years | |
| Secondary | Overall Survival (OS) | Up to 5 years | |
| Secondary | Concentrations of total linvoseltamab in serum | Up to 5 years | |
| Secondary | Occurrence of TEAEs | Up to 5 years | Phase 3 |
| Secondary | Severity of TEAEs | Up to 5 years | Phase 3 |
| Secondary | Occurrence of SAEs | Up to 5 years | Phase 3 |
| Secondary | Severity of SAEs | Up to 5 years | Phase 3 |
| Secondary | Occurrence of second primary malignancies | Up to 5 years | Phase 3 |
| Secondary | Change from baseline in Global Health Status (GHS) per European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) | Up to 5 years | Phase 3 The EORTC QLQ-C30 is a 30-item validated questionnaire developed to measure patient-reported Quality of Life (QoL). For GHS, scores range from 1 = "very poor" to 5 = "excellent" with higher scores indicating better functioning and positive changes from baseline indicate improvement. |
| Secondary | Change from baseline in physical functioning per EORTC QLQ-C30 | Up to 5 years | Phase 3 The EORTC QLQ-C30 is a validated 30-item questionnaire designed to measure patient-reported quality of life. Physical functioning is scored from 1 'very poor' to 5 'excellent,' with higher scores indicating better functioning; positive changes from baseline indicate improvement. |
| Secondary | Change from baseline in role functioning per EORTC QLQ-C30 | Up to 5 years | Phase 3 The EORTC QLQ-C30 is a validated 30-item questionnaire designed to measure patient-reported quality of life. Role functioning is scored from 1 'very poor' to 5 'excellent,' with higher scores indicating better functioning; positive changes from baseline indicate improvement. |
| Secondary | Change from baseline in pain per EORTC QLQ-C30 | Up to 5 years | Phase 3 The EORTC QLQ-C30 is a validated 30-item questionnaire designed to measure patient-reported quality of life. Pain is scored from 1 = "not at all" to 9 = "very much". Higher scores indicate higher symptom burden. |
| Secondary | Change from baseline in fatigue per EORTC QLQ-C30 | Up to 5 years | Phase 3 The EORTC QLQ-C30 is a validated 30-item questionnaire designed to measure patient-reported quality of life. Fatigue is scored from1 = "not at all" to 9 = "very much". Higher scores indicate higher symptom burden. |
| Secondary | Change from baseline in disease symptoms per EORTC QLQ- Multiple Myeloma Module 20 (MY20) | Up to 5 years | Phase 3 The EORTC QLQ-MY20 is a self-administered instrument to assess QoL in persons with MM. This 20-item questionnaire includes 6 items for disease symptoms. A high score for a symptom scale/item represents a high level of symptomatic problem. |
| Secondary | Change from baseline in treatment side effects per EORTC QLQ-MY20 | Up to 5 years | Phase 3 The EORTC QLQ-MY20 is a self-administered instrument to assess QoL in persons with MM. This 20-item questionnaire includes 10 items for treatment side effects. A high score for a symptom scale/item represents a high level of symptomatic problem. |
| Secondary | Change from baseline in body image per EORTC QLQ-MY20 | Up to 5 years | Phase 3 The EORTC QLQ-MY20 is a self-administered instrument to assess QoL in persons with MM. This 20-item questionnaire includes 1 item for treatment body image. A high score for a symptom scale/item represents a high level of symptomatic problem. |
| Secondary | Change from baseline in future perspective per EORTC QLQ-MY20 | Up to 5 years | Phase 3 The EORTC QLQ-MY20 is a self-administered instrument to assess QoL in persons with MM. This 20-item questionnaire includes 3 items for treatment future perspective. A high score for a symptom scale/item represents a high level of symptomatic problem. |
| Secondary | Change from baseline in EuroQoL-5 Dimensions 5-Level Questionnaire (EQ-5D-5L) Visual Analogue Scale (VAS) | Up to 5 years | Phase 3 The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: "no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems". The EQ VAS records the participant's self-rated health on a vertical visual analogue scale where the endpoints are labeled "Best imaginable health state" and "Worst imaginable health state". |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07428369/registered?page=2